Boehringer Ingelheim

#NEWS: Our investigational targeted therapy has been awarded a Commissioner’s National Priority Voucher from the U.S. FDA.

Find out more here go.boehringer.com/Fyr8N

#LifeForward #Oncology

#NEWS: 🧪 Building on our partnership in geographic atrophy, we’re launching a new collaboration with @cdr-life.bsky.social. Our aim is to advance antibody-based therapies for autoimmune diseases, such as lupus, multiple sclerosis and arthritis. Read more: go.boehringer.com/FOSjl

Boehringer acquires new pre-clinical program targeting autoimmune diseases.

#NEWS: We’ve acquired a pre-clinical program from Kyowa Kirin to develop small molecules targeting autoimmune diseases. Our aim is to address the root cause of these conditions and deliver long-lasting therapies. 🧪

Learn more: go.boehringer.com/MPRF

#Innovation #AutoimmuneDiseases #PharmSky

#NEWS: The National Medical Products Administration (NMPA) in China has approved our new treatment for idiopathic pulmonary fibrosis (#IPF).

🧪 Learn more here: go.boehringer.com/HdX1

The immune system has the remarkable ability to identify and eliminate cancer cells.

Our oncology research includes the investigation of T-cell engagers, focusing on leveraging immune mechanisms in cancer therapy.

Learn more 🧪: go.boehringer.com/Ki82v

#LifeForward #Oncology

#NEWS: Our latest oncology research in HER2 (ERBB2)-mutant advanced non-small cell lung cancer (NSCLC) has been presented at #ESMO25.

These advancements have the potential to fulfill patients’ unmet needs.

🧪 Find out more: go.boehringer.com/FU9K9

#LifeForward #Oncology

Living with cancer, the small, positive moments often have the biggest impact.

We're here to celebrate these 'Big Little Things': small victories, time with loved ones, and everyday joys.

🧪 Discover how these moments make a difference: go.boehringer.com/YomJY

#LifeForward #Oncology

#NEWS: Ten of our oncology abstracts will be presented at #ESMO25, sharing our ongoing research efforts in hard-to-treat cancers.

🧪 Learn more: go.boehringer.com/GCZ1

#LifeForward #Oncology

#NEWS:  The U.S. Food and Drug Administration (FDA) has approved the first new treatment for idiopathic pulmonary fibrosis (#IPF) in over a decade. 🧪

Learn more here: go.boehringer.com/rtx-w

#LifeForward

#NEWS: New pooled phase III data in idiopathic pulmonary fibrosis (IPF) and progressive pulmonary fibrosis (PPF) presented at the European Respiratory Society (ERS) Congress 2025: go.boehringer.com/rdYYD 🧪

 #ERS2025 #LifeForward

#NEWS: Our targeted cancer therapy for advanced non-small cell lung cancer (NSCLC) received Breakthrough Designation for first line use in the U.S. 🧪

Find out more here: go.boehringer.com/dz4O

#NEWS: New data available in HER2 (ERBB2)-mutant non-small cell lung cancer (NSCLC) in patients with stable, asymptomatic, and active brain metastases – underscoring our commitment to patients’ greatest needs.  🧪

Learn more about our presentation at #WCLC25: go.boehringer.com/WdAhL

We’re joining forces with @www.helmholtz-munich.de to drive new advances in fibrotic lung disease research. As leaders in fibrotic lung disease, we’re pioneering new therapies and striving towards our ultimate goal of finding a cure 🧪

Learn more: go.boehringer.com/HP-j5

#LungHealth #IPF

#NEWS for media: Our targeted cancer therapy has received approval in China for use in previously treated people with HER2 (ERBB2)-mutant advanced non-small cell lung cancer (NSCLC). 🧪

Learn more here: go.boehringer.com/YrIQ

#LifeForward #Oncology

A male researcher working in a lab

#NEWS: We are further strengthening our commitment to vision preservation by teaming up with Palatin Technologies. This partnership aims to develop a new first-in-class treatment for diabetic retinopathies. 🧪

Learn more: go.boehringer.com/py5Iu

#EyeHealth #DiabeticRetinopathy #Innovation

At 37, Samantha was diagnosed with non-small cell #lungcancer (NSCLC).

With support from her husband Justin and care team, she learned about #biomarker testing 🧪 to understand her cancer’s unique profile.

#LifeForward #Oncology #Medsky

#NEWS for media: Our targeted cancer therapy has been approved in the U.S. for people with HER2 (ERBB2)-mutant advanced non-small cell lung cancer by the U.S. @fda.gov‬.

Learn more here 👉: www.boehringer-ingelheim.com/human-health...

#LifeForward #Oncology

#NEWS: With Click Therapeutics, we’re excited to announce our Phase III clinical study in people with experiential negative symptoms of schizophrenia met its primary endpoint. This is an important step forward in advancing mental health care 🧪. Learn more: go.boehringer.com/cvjNF

H1 Results of Boehringer Ingelheim: Growth and pipeline progress

#NEWS: First Half of 2025

👉 EUR 14.0 billion in group net sales

👉 Zongertinib in #oncology and nerandomilast in #pulmonaryfibrosis near launch

👉 #AnimalHealth business grew by 7.6%

👉 Fast-growing pipeline in cardio-renal-metabolic diseases

Learn more ➡️ go.boehringer.com/w7ce3

#NEWS: We’re kicking off a new chapter in digital health through our collaboration with Eko Health to improve heart murmur detection in dogs. We will bring an AI-powered tool to veterinarians to give dogs and pet owners more years of life to love. 🐕 #LifeForward

Learn more: go.boehringer.com/4olwa

#NEWS: Tackling cardiovascular, renal and metabolic conditions together may be the key to hitting the UN’s 2030 goal of cutting early deaths from #NCDs by a third.

Explore how 16 countries are tackling these challenges in the global Future Health report, launched at #WHA78.
👉 bit.ly/4jeQ6WZ

#NEWS: Pivotal FIBRONEER™-IPF and FIBRONEER™-ILD phase III full data in IPF and PPF presented at #ATS2025 and published in @nejm.org. IPF and PPF are serious conditions that can cause irreversible lung damage and continued decline in lung function. 🧪 👉 go.boehringer.com/1fG0l

#LifeForward

A young man shows a tablet screen to an older man. The headline says "Progressing cancer care." and on the bottom right "Life forward".

#NEWS: We are joining forces with @tempusai.bsky.social

By combining our experimental data with Tempus AI's real-world data on its AI-powered platform, we aim to pave the way for novel cancer treatments.

Learn more: bit.ly/43owlqa

#DataScience #Cancer #ResearchCollaboration

#NEWS: By using ViVerita's in vivo screening platform, we strive to identify higher quality targets faster, with fewer failures to accelerate the delivery of novel treatments for cancer patients with high need. 🧪

#NEWS: Together with the University of Oxford and Cumulus Neuroscience we are investigating new wearable technology. This will help gain insights into brain activity of people living with psychiatric disorders and develop new #PrecisionPsychiatry treatments.

Learn more: bit.ly/4jsOIAN

We developed this campaign in collaboration with leading associations like the World Small Animal Veterinary Association, the World Association for Buiatrics, the American Association of Swine Veterinarians, and VetFamily.

#NEWS: New survey shows over 90% of animal owners trust and appreciate veterinary teams but underestimate the profession’s demands. Learn more: 👉 go.boehringer.com/o9qo

Survey conducted with Kynetec.

#WorldVeterinaryDay #LifeForward

Our mission is to redefine mental health care. We invest in research and forge unique partnerships to help transform lives. Though the journey is complex, we’re committed to ‘failing forward’— using every setback as a stepping stone toward progress. Learn more: bit.ly/42kZqSw #LifeForward

In our 2024 #AnnualReport Magazine titled 'Think Beyond' we reflect on our achievements and showcase some amazing stories and voices of our colleagues and other experts. Take a look at where we find our purpose, what drives us and where we strive to make a difference. ➡️ bit.ly/4cetX9m

#LifeForward

2024: More humans and animals served, pipeline on track

#PRESS: In 2024, we
👉 invested EUR 6.2 billion in R&D 🧪
👉 helped more than 66 million patients
👉 further advanced our sustainability efforts
👉 kept working on breakthrough solutions that improve lives of humans & animals. Check it out ➡️ bit.ly/3FMzAzg